Total Payments
$56,352
2024 Payments
$4,854
Companies
18
Transactions
80
Medicare Patients
1,213
Medicare Billing
$354,689
Payment Breakdown by Category
Consulting$40,325 (71.6%)
Other$7,920 (14.1%)
Travel$3,643 (6.5%)
Food & Beverage$2,579 (4.6%)
Research$1,885 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,325 | 14 | 71.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,920 | 2 | 14.1% |
| Travel and Lodging | $3,643 | 20 | 6.5% |
| Food and Beverage | $2,579 | 37 | 4.6% |
| Unspecified | $1,885 | 7 | 3.3% |
Payments by Type
General
$54,467
73 transactions
Research
$1,885
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $11,808 | 16 | $0 (2019) |
| PFIZER INC. | $11,196 | 2 | $0 (2017) |
| Exelixis Inc. | $10,168 | 20 | $0 (2023) |
| Janssen Research & Development, LLC | $6,241 | 6 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $6,048 | 12 | $0 (2024) |
| GENZYME CORPORATION | $3,281 | 8 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $2,460 | 1 | $0 (2024) |
| Eisai Inc. | $2,400 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $1,865 | 2 | $0 (2021) |
| Telix Pharmaceuticals | $377.45 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,854 | 7 | AstraZeneca Pharmaceuticals LP ($2,460) |
| 2023 | $5,954 | 13 | Regeneron Pharmaceuticals, Inc. ($4,574) |
| 2022 | $4,031 | 5 | GENZYME CORPORATION ($2,168) |
| 2021 | $7,898 | 15 | Exelixis Inc. ($5,467) |
| 2020 | $2,988 | 4 | Eisai Inc. ($2,400) |
| 2019 | $8,846 | 14 | Merck Sharp & Dohme Corporation ($6,187) |
| 2018 | $10,518 | 17 | Merck Sharp & Dohme Corporation ($5,621) |
| 2017 | $11,263 | 5 | PFIZER INC. ($11,196) |
All Payment Transactions
80 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $191.83 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | ||||||
| 11/25/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 11/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| 08/07/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $185.45 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 08/07/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 06/02/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $167.07 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 03/05/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/21/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 07/21/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: Oncology | ||||||
| 06/05/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $98.78 | General |
| Category: Oncology | ||||||
| 06/04/2023 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $71.26 | General |
| Category: Oncology | ||||||
| 06/04/2023 | Genentech, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $59.71 | General |
| Category: BioOncology | ||||||
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,312.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,734.00 | General |
| 03/16/2023 | Antares Pharma, Inc. | NOCDURNA (Drug), XYOSTED, TLANDO | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | ||||||
| 02/17/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $107.26 | General |
| Category: Oncology | ||||||
| 02/16/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $411.70 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER • Category: ONCOLOGY | ||||||
| 02/15/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 02/15/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 02/15/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $6.56 | General |
| 11/30/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $212.38 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER • Category: ONCOLOGY | ||||||
| 11/17/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| 11/08/2022 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,168.00 | General |
| 11/04/2022 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 10/26/2022 | Janssen Research & Development, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $150.66 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Regeneron Pharmaceuticals, Inc. | $1,693 | 6 |
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | Regeneron Pharmaceuticals, Inc. | $191.83 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 369 | 767 | $417,250 | $85,352 |
| 2022 | 8 | 331 | 798 | $421,146 | $93,888 |
| 2021 | 8 | 275 | 773 | $409,600 | $102,496 |
| 2020 | 8 | 238 | 627 | $290,199 | $72,953 |
Total Patients
1,213
Total Services
2,965
Medicare Billing
$354,689
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 244 | $129,450 | $26,714 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 165 | $122,100 | $26,492 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 138 | $52,440 | $10,360 | 19.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 73 | $30,550 | $7,741 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 83 | $43,990 | $7,084 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 26 | $19,240 | $3,313 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $11,880 | $2,566 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 20 | $7,600 | $1,081 | 14.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 112 | 390 | $206,146 | $45,297 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 106 | $78,440 | $17,698 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 93 | 167 | $63,460 | $13,681 | 21.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 12 | 60 | $32,400 | $8,099 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 31 | $20,460 | $4,722 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $13,280 | $3,311 | 24.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $2,880 | $566.56 | 19.7% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 16 | $4,080 | $513.74 | 12.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 65 | 238 | $153,580 | $40,232 | 26.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 90 | 268 | $132,290 | $31,914 | 24.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 12 | 78 | $42,120 | $10,508 | 24.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 68 | $26,520 | $6,478 | 24.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $20,750 | $5,302 | 25.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 52 | $18,560 | $4,399 | 23.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $11,880 | $2,893 | 24.4% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 12 | 26 | $3,900 | $770.16 | 19.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 67 | 196 | $99,960 | $26,057 | 26.1% |
About Dr. Mark Stein, MD
Dr. Mark Stein, MD is a Hematology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568549319.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Stein, MD has received a total of $56,352 in payments from pharmaceutical and medical device companies, with $4,854 received in 2024. These payments were reported across 80 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($40,325).
As a Medicare-enrolled provider, Stein has provided services to 1,213 Medicare beneficiaries, totaling 2,965 services with total Medicare billing of $354,689. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Medical Oncology
- Location New York, NY
- Active Since 11/01/2006
- Last Updated 03/01/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1568549319
Products in Payments
- XTANDI (Drug) $11,191
- CABOMETYX (Drug) $5,575
- KEYTRUDA (Biological) $5,000
- Cabometyx (Drug) $4,594
- OPDIVO (Biological) $1,845
- NO PRODUCT DISCUSSED (Drug) $1,113
- LIBTAYO (Biological) $624.08
- ILLUCCIX (Drug) $377.45
- ERLEADA (Drug) $247.42
- PADCEV (Biological) $104.46
- BAVENCIO (Drug) $98.78
- LIBTAYO (Drug) $75.00
- Tecentriq (Biological) $59.71
- EXPAREL (Drug) $42.94
- NOCDURNA (Drug) $17.17
- ASTRA TECH Implant System (Device) $13.49
- INLYTA (Drug) $4.70
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in New York
Dr. Barry Coller, M.d, M.D
Hematology — Payments: $10.2M
Hematology $10.2M
Dr. Dan Douer, M.d, M.D
Hematology — Payments: $665,161
Hematology $665,161
Louis Aledort, Md, MD
Hematology — Payments: $377,491
Hematology $377,491
Michael Mauro, Md, MD
Hematology — Payments: $374,307
Hematology $374,307
Faith Davies, Md, MD
Hematology — Payments: $373,421
Hematology $373,421
Ann Jakubowski, Md, MD
Hematology — Payments: $92,726
Hematology $92,726